<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01409876</url>
  </required_header>
  <id_info>
    <org_study_id>HistoBrachy1</org_study_id>
    <nct_id>NCT01409876</nct_id>
  </id_info>
  <brief_title>HistScanning- Based PDR Brachytherapy in Prostate Cancer HistoScanning- Based Interstitial PDR Brachytherapy</brief_title>
  <official_title>HistoScanning- Based Dose-painting Image-guided Interstitial PDR-brachytherapy in Prostate Cancer - a Phase II Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Erlangen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Erlangen</source>
  <brief_summary>
    <textblock>
      This is a phase II trial looking at the feasibility of HistoScanning- based dose-painting&#xD;
      image- guided interstitial brachytherapy in non- metastatic prostate cancer&#xD;
&#xD;
      Endpoints:&#xD;
&#xD;
      Primary endpoint Evaluation of the feasibility of HistoScanning- based dose-painting image-&#xD;
      guided interstitial brachytherapy&#xD;
&#xD;
      Secondary endpoints&#xD;
&#xD;
        1. Evaluating tumor response using HistoScanning&#xD;
&#xD;
        2. Evaluating locoregional recurrence rates by measuring PSA&#xD;
&#xD;
        3. Analysis of the correlation between tumor response as determined by HistoScanning and&#xD;
           PSA response&#xD;
&#xD;
        4. Evaluating the safety dose-painting image- guided interstitial brachytherapy by&#xD;
           recording serious adverse events&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rationale:&#xD;
&#xD;
      The study is designed as a prospective monocentric phase II trial. The choice of the&#xD;
      therapeutic concept is governed by the risk group that the patient falls into. Risk groups&#xD;
      are defined according to the classification by D' Amico.&#xD;
&#xD;
      The following concepts will be used:&#xD;
&#xD;
      HDR brachytherapy: 19,0- 38 Gy / 2-4 fractions (2-4 x 9,5 Gy)&#xD;
&#xD;
      PDR brachytherapy: 35-70 Gy / 50 --100 pulses(1 puls/h, 24 h/d)&#xD;
&#xD;
      Dose painting the timorous areas as seen in HistoScanning as covered with a dose&#xD;
      Dref2&gt;130-150%&#xD;
&#xD;
      External beam radiotherapy will be used in addition to brachytherapy for intermediate and&#xD;
      high risk patients. The following concepts will be used 50,40 Gy / 28 fractions at 1.8 Gy&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>September 2011</start_date>
  <completion_date type="Anticipated">September 2016</completion_date>
  <primary_completion_date type="Anticipated">September 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of the feasibilty of histoscanning- based dose-painting image- guided interstitial brachytherapy</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>assessing tumor response and side effects</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Brachytherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>brachytherapy</intervention_name>
    <description>interstitial image- guided PDR/HDR brachytherapy</description>
    <arm_group_label>Brachytherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically proven prostate cancer&#xD;
&#xD;
          -  All cT1-3 carcinomas independent of grading and PSA value&#xD;
&#xD;
          -  Prostate volume&lt; 70cc&#xD;
&#xD;
          -  No distant metastases&#xD;
&#xD;
          -  Karnofsky &gt; 60&#xD;
&#xD;
          -  Written informed consent from the patient regarding study participation&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  All patients who do not meet the inclusion criteria&#xD;
&#xD;
          -  T4 carcinomas&#xD;
&#xD;
          -  Proven metastases N+ and/or M1&#xD;
&#xD;
          -  Epidural or general anaesthesia not possible&#xD;
&#xD;
          -  Pathological clotting parameters&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sebastian Lettmaier, MD</last_name>
    <phone>09131 85 44216</phone>
    <email>sebastianlettmaier@uk-erlangen.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Radiation Therapy University Hospital</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Vratislav Strnad, MD, Prof</last_name>
      <phone>+49 9131 85 33419</phone>
      <email>vratislav.strnad@uk-erlangen.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>March 2011</verification_date>
  <study_first_submitted>August 3, 2011</study_first_submitted>
  <study_first_submitted_qc>August 3, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 4, 2011</study_first_posted>
  <last_update_submitted>August 3, 2011</last_update_submitted>
  <last_update_submitted_qc>August 3, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 4, 2011</last_update_posted>
  <responsible_party>
    <name_title>Sebastian Lettmaier</name_title>
    <organization>University Hospital Erlangen</organization>
  </responsible_party>
  <keyword>histoscanning</keyword>
  <keyword>brachytherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

